Skip to main content

Seres Therapeutics, Inc.

MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001609809

In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 39 institutions reported holding it in 13F filings for Q3 2026, worth $7.84M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$13.6M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $794.88 in total
4
13F holdersQ3 2026, +5 vs. previous quarter
39
13F valueReported value at the end of Q3 2026
$7.84M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$789.0K
No comparable prior period
Net income, FY2025
$5.70M
+4,088.2% year over year
Free cash flow, FY2025
$865.0K
No comparable prior period
Revenue, Q3 FY2026
$593.0K
+68.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net income for FY2025: $5.70M (721.9% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
342.2K
Shares sold short
Change
+29.9K
+9.6% vs. previous
Days to cover
4.31
At average daily volume

Superinvestors holding MCRB, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding MCRB at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Seres Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 17, 2026 (view filing)4:15 PM ETNov 161 dayBrady KellySee RemarksSSale−85$1.38−$117.3−1.0%8.78K after10b5-1
Nov 17, 2026 (view filing)4:15 PM ETNov 161 dayDesRosier ThomasSee RemarksSSale−103$1.38−$142.14−1.2%8.26K after10b5-1
Nov 17, 2026 (view filing)4:15 PM ETNov 161 dayShaff Eric D.DirectorSSale−287$1.38−$396.06−2.2%12.9K after10b5-1
Nov 17, 2026 (view filing)4:15 PM ETNov 161 dayHenn Matthew R.See RemarksSSale−101$1.38−$139.38−1.2%8.13K after10b5-1
Aug 18, 2026 (view filing)5:33 PM ETAug 171 dayBrady KellySee RemarksSSale−64$4.55−$291.2−0.7%8.68K after10b5-1
Aug 18, 2026 (view filing)5:27 PM ETAug 171 dayShaff Eric D.DirectorSSale−263$4.55−$1.20K−2.1%12.5K after10b5-1
Aug 18, 2026 (view filing)5:25 PM ETAug 171 dayHenn Matthew R.See RemarksSSale−81$4.55−$368.55−1.0%8.00K after10b5-1
Aug 18, 2026 (view filing)5:22 PM ETAug 171 dayDesRosier ThomasSee RemarksSSale−82$4.55−$373.1−1.0%8.12K after10b5-1
May 19, 2026 (view filing)May 181 dayShaff Eric D.DirectorSSale−259$7.53−$1.95K−2.1%12.0K after10b5-1
May 19, 2026 (view filing)May 181 dayBrady KellySee RemarksSSale−59$7.53−$444.27−0.7%8.56K after

Top 10 13F holders, Q3 2026

See all 39 holders

The largest institutional positions in Seres Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding MCRB in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Flagship Pioneering Inc.1,155,850$3.87M0.20%00.0%Unchanged
Vanguard Capital Management LLC286,405$959.5K0.00%−1,371−0.5%Reduced
Marshall Wace, LLP139,278$466.6K0.00%−32,967−19.1%Reduced
Jacobs Levy Equity Management, Inc134,375$450.2K0.00%+134,375New
Vontobel Holding Ltd.114,566$383.8K0.00%−8,409−6.8%Reduced
BlackRock, Inc.109,827$367.9K0.00%−1,173−1.1%Reduced
Geode Capital Management, LLC78,898$264.4K0.00%−1,076−1.3%Reduced
Susquehanna International Group, LLP62,692$210.0K0.00%+4,364+7.5%Added
Vanguard Fiduciary Trust Co48,685$163.1K0.00%00.0%Unchanged
State Street Corp33,901$113.6K0.00%00.0%Unchanged